Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
|Articles|March 20, 2018
Thermo Fisher Expands Clinical Distribution in Europe
Author(s)BioPharm International Editors
An expanded pharma services supply chain facility in Germany boosts Thermo Fisher’s Pharma Services footprint in Europe.
Advertisement
Thermo Fisher Scientific announced plans to increase the company’s capacity in Europe for cold and ambient clinical trial materials by investing $35 million in a pharma services supply chain facility in Rheinfelden (Baden) Germany.
The facility will be scalable for mixed-use space and provide a “strategic logistical location” for shipping by road or air, the company reported in a March 16, 2018 press statement. Plans for the facility, which will provide up to 200 new jobs locally, were announced at a Rheinfelden council meeting.
Construction of the 8000-sq.-m expansion is scheduled to begin in the fourth quarter of 2018 with completion in 12–18 months. The investment includes the option for additional expansion that could potentially double the footprint, the company reports. The new facility will address requirements for drug supply safety including Clinical Trial Regulations Annex 6 and the Falsified Medicines Directive to be implemented in 2019.
Thermo Fisher’s Pharma Services includes Patheon’s drug development and manufacturing services and Fisher Clinical Services.
Source:
Advertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5